Skip to content
OpenCapital
Get started

Vor Biopharma VOR Q1 2026 earnings

Reported May 13, 2026 · After market close

Diluted EPS-$0.73Beat by $0.02
EPS estimate-$0.75

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.69

Financials

Q1 2026

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$1.07B+873%
Enterprise value$903.24M+902%

Returns & leverage

See full
Current ratio31.1×+27.3×

Versus estimates

Diluted EPS

Q1 2026-$0.73Beat by $0.02
Q4 2025$82.04Beat by $83.18Q3 2025-$3.33Miss by $0.27Q2 2025-$43.60Miss by $32.20Q1 2025-$0.26Miss by $0.01Q4 2024-$0.44Miss by $0.10

Ask the moment Vor Biopharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Vor Biopharma report Q1 2026 earnings?
Vor Biopharma (VOR) reported Q1 2026 earnings on May 13, 2026 after market close.
What were Vor Biopharma's Q1 2026 revenue and EPS?
Vor Biopharma reported diluted EPS of $-0.73 for Q1 2026.
Did Vor Biopharma beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.75 by $0.02.
How did Vor Biopharma's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 180.8% from $-0.26.
Where can I find Vor Biopharma's Q1 2026 SEC filings?
You can read the 10-Q periodic report (0001193125-26-220689) directly on SEC EDGAR. The filing index links above go to sec.gov.